Novo Nordisk unveils Wegovy sales

Friday, pharmaceutical firm Novo Nordisk has publicized its quarterly report, in which the company reveals for the very first time exact sales figures for obesity drug Wegovy, beating analysts’ best bets by far.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Since launching obesity treatment Wegovy on the US market in June of last year, Novo Nordisk has not wanted to report on individual sales within its Obesity Care business.

With Novo Nordisk’s first quarterly report on Friday, this has ostensibly changed. The report is also out half a week before it was scheduled.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs